Pharmacokinetics & Drug Delivery | Antimicrobial Agents | Gastrointestinal Pharmacology | Methods for Diagnostic & Therapeutic Studies | Liver Failure & Liver Disease | Viral Hepatitis
Improved predictive value for sustained immune control in peginterferon alfa-2a (40KD) (PEGASYS)-treated HBeAg-positive patients using combined HBsAg and HBV DNA levels at week 24
Teerha Piratvisuth*, Henry LY Chan, Patrick Marcellin, Cynthia Wat, Loredana Regep, Diethelm Messinger, Hans-Peter Kapprell, Zhi-Meng Lu, Kang Xian Luo
*Corresponding author: Teerha Piratvisuth
NKC Institute of Gastroenterology and Hepatology, Department of Medicine, Prince of Songkla University, Hat Yai, Thailand
F1000Posters 2012, 3: 470 (poster) [English]
Poster [1.37 MB] | Recommended by F1000Prime
Presented at
47th Annual International Liver Congress 2012,
18 - 22 Apr 2012, 538
The aim was to investigate whether combined HBsAg and HBV DNA levels on-treatment can improve prediction of sustained response post-treatment in HBeAg-positive patients treated with Peg-IFN alpha-2a monotherapy for 48 weeks in a Phase III registration trial.
The on-treatment combined rule of using HBsAg + HBV DNA at week 24 improved negative predictive values (NPVs) for both HBeAg seroconversion and combined response 6 months post-treatment. Using these two parameters together, a high NPV of 98% is observed for combined response in patients treated with 48 weeks of Peg-IFN alpha-2a monotherapy. This result can provide useful information to clinicians, allowing them to take timely treatment decisions and potentially stop or modify treatment in HBeAg-positive patients with low chance of response observed early on-treatment.
Corresponding author Teerha Piratvisuth has participated on advisory boards for Roche, Novartis, MSD and Glaxo Smith Kline. Teerha has also participated in speaker’s bureau for Roche, Novartis, MSD, Glaxo Smith Kline and BMS, and has received research grants from both Roche and Novartis.
F. Hoffmann-LaRoche Ltd., ClinicalTrials.gov Identifier: NCT00048945
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
